| Closed |
S0530 |
Phase II Relapsed or Refractory ALL |
10/1/2006 |
8/1/2008 |
100% |
|
Published
|
| Closed |
S0434 |
Phase II Relapsing/Resistant Myeloma Previously Treated with Bortezomib |
3/15/2006 |
|
58% |
|
Published
|
| Closed |
S0605 |
Phase II Revlimid Untreated Non-M3, 5q- AML and >= Age 60 |
6/15/2006 |
7/1/2010 |
91% |
|
Published
|
| Closed |
S0933 |
Phase II RO4929097 in Adv Melanoma |
10/28/2010 |
11/15/2011 |
45% |
|
Published
|
| Closed |
S0816 |
Phase II Stage III-IV Hodgkin's: FDG-PET Imaging Study |
7/1/2009 |
12/1/2012 |
100% |
|
Published
|
| Closed |
SWOG-8823 |
Phase II Study of Continuous Infusion Recombinant Interleukin-2 (r-IL2) in Patients with Colorectal Carcinoma |
4/1/1989 |
11/15/1990 |
14% |
|
|
| Closed |
SWOG-9030 |
Phase II Study of High Dose ARA-C/Mitoxantrone for the Treatment of Relapsed/Refractory Acute Lymphocytic Leukemia |
11/1/1991 |
5/15/1994 |
60% |
|
Published
|
| Closed |
SWOG-8993 |
Phase II Study of High Dose Melphalan with Hemopoietic Stem Cell Support and GM-CSF in Refractory Multiple Myeloma (MM) |
4/15/1991 |
5/1/1996 |
100% |
|
Published
|
| Closed |
S1929 |
Phase II Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (SCLC) |
6/15/2020 |
12/15/2022 |
100% |
|
|
| Closed |
SWOG-8517 |
Phase II Study of Platinum and Mitoxantrone in the Treatment of Metastatic Adenocarcinoma of the Prostate |
2/10/1986 |
8/1/1987 |
|
|
Published
|
| Closed |
SWOG-8630 |
Phase II Study of Recombinant DNA Gamma Interferon in Advanced Colorectal Cancer |
5/15/1987 |
11/15/1988 |
|
|
Published
|
| Closed |
SWOG-8742 |
Phase II Study of Recombinant Tumor Necrosis Factor (rTNF) in Patients with Metastatic Sarcoma |
8/1/1988 |
12/1/1989 |
|
|
Published
|
| Closed |
SWOG-8626 |
Phase II Study of Recominbant DNA Gamma Interferon in Advanced Cancer of the Pancreas |
5/15/1987 |
11/15/1988 |
|
|
Published
|
| Closed |
SWOG-9413 |
Phase II Treatment with Etoposide (E), Leucovorin (L), 5-Fluorouracil (F) and Interferon Alpha 2b (I), (ELFI) + G-CSF for Locally Advanced or Recurrent Pancreatic Adenocarcinoma |
5/1/1995 |
3/15/1996 |
100% |
|
Published
|
| Closed |
SWOG-8811 |
Phase II Trial of 5-Fluorouracil and High Dose Folinic Acid as First or Second Line Therapy for Advanced Breast Cancer |
9/1/1988 |
11/15/1990 |
77% |
|
Published
|
| Closed |
SWOG-9326 |
Phase II Trial of Altretamine for Consolidation of Clinical Complete Response in Patients with Stage III Epithelial Ovarian Cancer |
9/1/1993 |
7/1/1997 |
100% |
|
Published
|
| Closed |
SWOG-9429 |
Phase II Trial of Carboplatin and VP-16 With Concurrent For Poor-Risk Stage III Non-Small Cell Lung Carcinoma |
8/15/1994 |
9/1/1995 |
100% |
|
Published
|
| Closed |
S9618 |
Phase II Trial of Carboplatin Followed by Dose Intense Paclitaxel, Followed by Maintenance Paclitaxel Therapy in Stage IV Ovarian, Fallopian Tube and Peritoneal Cancers |
10/1/1996 |
9/15/1999 |
96% |
|
Published
|
| Closed |
SWOG-9235 |
Phase II Trial of Casodex in Advanced Prostate Cancer Patients Who Failed Conventional Hormonal Manipulation |
12/15/1993 |
6/1/1994 |
96% |
|
Published
|
| Closed |
S9705 |
Phase II Trial of Cisplatin, Etoposide and Paclitaxel (Taxol®) With G-CSF in Untreated Patients with Extensive Small Cell Lung Cancer |
8/15/1997 |
7/1/1998 |
100% |
|
Published
|
